These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 27402995)

  • 21. Assessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthy women.
    Démolis JL; Strabach S; Vacheron F; Funck-Brentano C
    Br J Clin Pharmacol; 2005 Aug; 60(2):120-7. PubMed ID: 16042664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of drug-induced QT interval prolongation on drug discovery and development.
    Fermini B; Fossa AA
    Nat Rev Drug Discov; 2003 Jun; 2(6):439-47. PubMed ID: 12776219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prevalence of QT prolongation in a population of patients with substance use disorders.
    Scott AJ; Dunlop AJ; Brown A; Sadler C; Isbister GK
    Drug Alcohol Rev; 2017 Mar; 36(2):239-244. PubMed ID: 27241860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K; Witchel HJ; McCulloch J; Sharkey J
    Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
    Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
    J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protease inhibitor-associated QT interval prolongation.
    Hunt K; Hughes CA; Hills-Nieminen C
    Ann Pharmacother; 2011 Dec; 45(12):1544-50. PubMed ID: 22128044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probable quetiapine-mediated prolongation of the QT interval.
    Aghaienia N; Brahm NC; Lussier KM; Washington NB
    J Pharm Pract; 2011 Oct; 24(5):506-12. PubMed ID: 21844216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency and prognostic significance of QT prolongation in chronic renal failure patients.
    Voiculescu M; Ionescu C; Ismail G
    Rom J Intern Med; 2006; 44(4):407-17. PubMed ID: 18386617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferences of the autonomic nervous system with drug induced QT prolongation: a point to consider in non-clinical safety studies.
    Champeroux P; Ouillé A; Martel E; Fowler JS; Maurin A; Jude S; Lala P; Le Guennec JY; Richard S
    J Pharmacol Toxicol Methods; 2010; 61(3):251-63. PubMed ID: 20172034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study.
    Charbit B; Alvarez JC; Dasque E; Abe E; Démolis JL; Funck-Brentano C
    Anesthesiology; 2008 Aug; 109(2):206-12. PubMed ID: 18648229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between C-reactive protein, corrected QT interval and presence of QT prolongation in hypertensive patients.
    Chang KT; Shu HS; Chu CY; Lee WH; Hsu PC; Su HM; Lin TH; Voon WC; Lai WT; Sheu SH
    Kaohsiung J Med Sci; 2014 Jun; 30(6):310-5. PubMed ID: 24835352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
    Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
    Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Preventive treatment of prolongation of the QT interval].
    Szponar J; Zapalska-Pozarowska K; Szponar E
    Przegl Lek; 2012; 69(8):535-40. PubMed ID: 23243922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heart rate correction models to detect QT interval prolongation in novel pharmaceutical development.
    Markert M; Shen R; Trautmann T; Guth B
    J Pharmacol Toxicol Methods; 2011; 64(1):25-41. PubMed ID: 21635956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New formula for evaluation of the QT interval in patients with left bundle branch block.
    Bogossian H; Frommeyer G; Ninios I; Hasan F; Nguyen QS; Karosiene Z; Mijic D; Kloppe A; Suleiman H; Bandorski D; Seyfarth M; Lemke B; Eckardt L; Zarse M
    Heart Rhythm; 2014 Dec; 11(12):2273-7. PubMed ID: 25149024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effects of the Adenosine Receptor Antagonists on the Reverse of Cardiovascular Toxic Effects Induced by Citalopram In-Vivo Rat Model of Poisoning.
    Büyükdeligöz M; Hocaoğlu N; Oransay K; Tunçok Y; Kalkan Ş
    Balkan Med J; 2015 Jul; 32(3):303-8. PubMed ID: 26185720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation.
    Malik M
    Drug Saf; 2016 Jul; 39(7):647-59. PubMed ID: 26968542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of positive controls in assessing assay sensitivity in ICH S7B and ICH E14 guidance for evaluation of QT/QTc interval prolongation.
    Chiang AY; Mallinckrodt CH; Dmitrienko AA; Leishman DJ
    J Pharmacol Toxicol Methods; 2010; 62(2):143-7. PubMed ID: 20570744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study.
    Mumford JL; Wu K; Xia Y; Kwok R; Yang Z; Foster J; Sanders WE
    Environ Health Perspect; 2007 May; 115(5):690-4. PubMed ID: 17520054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.